Kornimate/medical-research-clean huggingface dataset:
conquer fear support intervention in supporting patients with stage iii-iv lung or gynecologic cancer

Conditions: Advanced Lung Carcinoma; Malignant Female Reproductive System Neoplasm; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8

Summary: this trial will pilot a psychosocial intervention called conquer fear support (cfs) in patients with stage iii-iv lung or gynecologic cancer who are experiencing fear of cancer progression. the intervention is adapted from a novel program called "conquer fear" which was developed by researchers in australia. cfs may help in reducing worries, fears, and uncertainty in patients with advanced lung or gynecological cancer.

primary objectives: i. assess the feasibility and acceptability of the cfs intervention in patients with advanced lung and gynecologic (gyn) cancer (stages iii or iv) who have clinically significant levels of fear of cancer progression (fop) or cancer-related distress. secondary objectives: i. assess preliminary effects of the intervention on fop, cancer-specific distress, anxiety, depression, overall symptom distress, metacognitions, and mindfulness. outline: patients attend cfs psychosocial intervention consisting of 7 nurse-led sessions (session 1 in-person and sessions 2-7 via video conferencing) over 45 minutes each for 8 weeks. patients also complete home practice assignments comprising attention training technique and mindfulness practice sessions after each session. after completion of study intervention, patients are followed up at week 12.

Eligibility criteria:
inclusion criteria: * patients with gynecologic (gyn) and lung cancer will be recruited * stage iii or iv disease * at least 3 months from initial diagnosis * receiving disease-focused treatment or active surveillance mode * a score of ≥ 34 on the fear of progression questionnaire-short form (sf) or ≥ 24 on the impact of event scale-revised * all subjects must have the ability to understand and the willingness to sign a written informed consent exclusion criteria: * current severe depression or psychosis; significant cognitive impairment * patients enrolled in hospice care or who opt to receive no further disease-focused treatment * patients who are currently receiving ongoing psychiatric treatment * non-english speaking
visual function tests in age-related macular degeneration

Conditions: Age Related Macular Degeneration

Summary: the goal of this study is to assess a battery of visual function tests in subjects with non-exudative age-related macular degeneration

age-related macular degeneration (amd) is one of the leading causes of visual impairment among elderly populations in developed countries. majority of amd patients (80%) suffer from the dry or non-exudative form of the disease. currently there are no approved treatments for dry amd. clinical development of therapeutic agents for dry amd is limited by slow progressing nature of the disease as well as the lack of sensitive endpoints to assess therapeutic efficacy. visual acuity, the commonly used functional endpoint, remains minimally affected during early stages of dry amd. thus novel visual function endpoints, that can identify functional deficits during early stages of dry amd prior to development of geographic atrophy, are needed. in the current study a battery of visual function tests will be evaluated in subjects with different stages of dry amd and normal controls, to assess their sensitivity and feasibility as potential functional endpoints for dry amd.

Eligibility criteria:
inclusion criteria: * all subjects must: 1. be 60 years of age or older; 2. provide written informed consent; 3. be willing and able to follow all instructions and attend the study visits; 4. must be able to perform all study procedures; normal subjects: 5. have bcva of 20/25 or better in the study eye; 6. have no history or clinical evidence of amd, retinal diseases or any other ocular pathologies in either eye; amd subjects: 7. have bcva of 20/40 or better in the study eye; 8. have a clinical diagnosis of non-exudative amd in the study eye; exclusion criteria: all subjects must not have any of the below criteria 1. have a diagnosis of wet amd in the study eye; 2. have any other hereditary or acquired retinal diseases in either eye ; 3. have glaucoma or other optic nerve diseases in either eye; 4. have corneal or other anterior segment diseases in either eye; 5. have significant cataract in the study eye; 6. have a history of ocular trauma or ocular surgery (other than cataract removal) in the study eye; 7. have a history of uncontrolled systemic disease (e.g. poorly controlled hypertension or poorly controlled diabetes); 8. have a history of seizures; 9. on psychotropic medications; 10. any other symptoms or conditions that could, in the opinion of the investigator, interfere with study procedures.

Keywords: visual function critical flicker fusion dark adaptation reading test
comparisons therapeutic effects of different peld procedure on lss.

Conditions: Degeneration Disc; Lumbar Spinal Stenosis

Summary: different procedure of percutaneous endoscopic lumbar discectomy (peld) was with ventral decompression of dural sac on the lumbar spinal stenosis remains unkonwn.the traditional transforaminal endoscopic spine system (tessys) of peld has been used in clnical for many years, but cannot achieve dorsal decompression. a newly developed modified tessys procedure, "u" route peld combining ventral and dorsal decompression was introduced. nevertheless, the superior between tessys and "u" route peld procedures on treating lss remains unknown. this study is desinged to recruit degenerative lumbar spinal stenosis patients who underwent tessys or "u" rout peld, recruited from january 2014 to december 2017. these patients will be followed up for 2 years, and assessed the minimum dura sac cross sectional area (mdcsa) by mri, and visual analogue scale (vas) and oswestry disability index (odi) at pre- and post-operation. the global clinical outcomes were evaluated using modified macnab criteria postoperatively. thus, comprehensively evaluate the safety and therapeutic effects of the two peld procedures on lss treatments.


Eligibility criteria:
inclusion criteria: * (1) patients with the diagnosis of degenerative lumbar spinal stenosis (lss) (central stenosis with or without lateral recess stenosis) on mono or double segments, with the imaging evidence of magnetic resonance images (mri) and computed tomography (ct); (2) patients presented low back pain, limp and sciatica, and have accepted conservative treatment more than 3 months but failed in symptoms relief; (3) patients agreed to accept tessys or the "u" route peld procedure over other spinal surgeries; (4) patients had lumbar mri imaging examines in our hospital at pre- and post-operation. exclusion criteria: * (1) patients with spinal instability, including dynamic instability or more than grade ii spondylolisthesis; (2) patients had spinal surgical history; (3) patients with peripheral nerve disease, systematic infection, bleeding diathesis or high risk of bleeding that cannot tolerate the surgery; (4) patients with mental illness and were uncooperative; (5) patients lost to the follow up.

Keywords: percutaneous endoscopic lumbar discectomy minimally invasive transforaminal endoscopic spine system u route
efficacy and security of intrapleurally alteplase vs urokinase for the treatment of complicated parapneumonic effusion and empyema

Conditions: Empyema, Pleural; Pleural Effusion; Pleural Diseases

Summary: 1. objectives: * main objective: to evaluate the efficacy and safety of intrapleural alteplase vs urokinase in patients with complex complicated parapneumonic pleural effusion and empyema. * to evaluate the pleural and plasmatic levels of the fibrinolytic system markers after the treatment with alteplase vs urokinase * to evaluate the safety of alteplase in the treatment of complex complicated parapneumonic pleural effusion and empyema 2. design: multicentric, randomized, parallel, controlled and double blind 3. main variable: percentage of curation 4. study population and number of patients: 204 patients with complex complicated parapneumonic pleural effusions and empyema 5. duration of the treatment: three days (main variable), and optional three days (secondary variable)


Eligibility criteria:
inclusion criteria: * empyema and complex complicated parapneumonic pleural effusion exclusion criteria: * pregnancy or breastfeeding * critically illness * systemic anticoagulant treatment * coagulation disorder * bronchopleural fistula * active bleeding * recent punction of noncompressive artery * stroke in the last 6 months * major intervention o major traumatism in the last 6 weeks * hypersensibility to urokinase or alteplase * severe liver or kidney failure * inclusion in another interventional study in the last month
[f-18]fluoro-dopa pet imaging of brain tumors in children

Conditions: Brain Tumors

Summary: the first phase of the study will investigate if there is increased uptake of \[f-18\]fdopa in pediatric brain tumors when compared to normal brain tissue.

the first phase of the study will investigate if there is increased uptake of \[f-18\]fdopa in pediatric brain tumors when compared to normal brain tissue. tne subjects between ages 5 and 17 years will be studies, to determine if there is increased uptake of \[f-18\]fdopa in pediatric brain tumors when compared to normal brain tissue. drug safety will also be monitored.

Eligibility criteria:
inclusion criteria: * documented brain tumor at diagnosis or relapse, including high grade glioma, low grade glioma, medulloblastoma including pnet, optic pathway glioma, brainstem glioma, ependymoma. exclusion criteria: * pregnancy * requirement for sedation * lack of informed consent

Keywords: brain tumors, children
pulmonary mechanics during minimally invasive repair of pectus excavatum

Conditions: Pectus Excavatum

Summary: the aim of the current study was to compare the effects of sevoflurane and desflurane on respiratory mechanics in patients undergoing repair of pectus excavatum.

the minimally invasive technique for pectus excavatum repair was introduced by nuss and colleagues using a metal bar to lift the depressed chest wall. this surgical procedure is usually done under general anesthesia with tracheal intubation. after inserting metal bar into the chest wall, decreased lung compliance was shown. previous studies demonstrated that administering desflurane during anesthesia resulted in marked increases in respiratory mechanical parameters, especially in the children with airway susceptibility. our primary hypothesis was that desflurane would cause an increase in respiratory resistance and a decrease in lung compliance compared to sevoflurane during repair of pectus excavatum.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of pectus excavatum * undergoing minimally invasive repair exclusion criteria: * younger than 15 year old * history of upper respiratory tract infection within recent 2 weeks * asthma * chronic obstructive pulmonary disease * previous treatment with bronchoactive drugs (b-agonist or antagonist, theophyline, anticholinergics and corticosteroid) * history of neurological deficits

Keywords: respiratory resistance lung compliance desflurane sevoflurane
collagenase option for reduction of dupuytren's contracture in japan

Conditions: Dupuytren's Contracture

Summary: to investigate the efficacy and safety of ak160 in patients with dupuytren's contracture. to determine plasma concentration after the first injection of ak160 in patients with dupuytren's contracture.


Eligibility criteria:
inclusion criteria: * at least 20 years old when written informed consent is obtained. * having a diagnosis of dupuytren's contracture and flexion contracture due to palpable cord in at least 1 non-thumb finger (20° to 100° in mp joint and 20° to 80° in pip joint). * positive tabletop test result (i.e., cannot simultaneously place affected finger and palm on a table). * voluntary written informed consent is obtained. exclusion criteria: patients meeting any of the following criteria will be excluded: * is pregnant, may be pregnant, wishes to become or could become pregnant during the study (i.e., unless acceptable contraception is used, the patient has been sterilized, or the patient is postmenopausal \[no menstrual period for at least 12 months without any other medical cause\]), or is breastfeeding. * has a coexisting chronic disease of the hand that could impact assessment (muscular disease, neurological disease, neuromuscular disease). * has received another investigational product 30 or fewer days before first injection of the investigational product. * has undergone aponeurectomy, aponeurotomy, needle aponeurotomy/fasciotomy, verapamil/interferon injection, or another dupuytren's contracture treatment of the primary joint 90 or fewer days before first injection of the investigational product. * is allergic to collagenase or any of the excipients of ak160. * has taken tetracycline derivative such as minocycline and doxycycline 14 or fewer days before first injection of the investigational product. * has received a collagenase product 30 or fewer days before first injection of the investigational product. * is currently taking or has taken, 7 or fewer days before first injection of the investigational product, an anticoagulant or antiplatelet drug (other than ≤150 mg/day of aspirin). * has suffered a recent stroke, hemorrhage, or other disease affecting the hands. * has a serious disease unsuited for the study. * receiving treatment for a malignancy. * history of drug or alcohol addiction within the past 5 years or history of drug or alcohol abuse within the past year. * has received previously the investigational product (ak160, aa4500, xiaflex®, or xiapex®). * otherwise found ineligible as a subject by the investigator.

Keywords: ak160, collagenase clostridium histolyticum
hydroxyapatite (ha) coating versus plasma porous spray (pps) in press-fit acetabular components early outcomes with dexa

Conditions: Osteoarthritis

Summary: the study design comprises a randomized trial of patients undergoing primary total hip arthroplasty using the g7 acetabular system and taperloc complete stem comparing regular plasma porous spray with ha coating using bonemaster (bm) in an uncemented cup. dexa scanning will be used to measure periprosthetic bone mineral density. clinical evaluations will be conducted .

the study design comprises a randomized trial of patients undergoing primary total hip arthroplasty using the g7 acetabular system and taperloc complete stem comparing regular plasma porous spray with ha coating using bonemaster (bm) in an uncemented cup. dexa scanning will be used to measure periprosthetic bone mineral density preoperatively and post-operatively at 6 weeks, 12 weeks, 26 weeks, and 12 months for both the treated and contralateral hip joint. clinical evaluations will be conducted preoperatively, and postoperatively at 6, 12, 26 weeks, 12 months and 24 months.

Eligibility criteria:
inclusion criteria: 1. patients with osteoarthritis who are candidates for a primary total hip replacement with uncemented acetabular and femoral components as determined by the surgeon. 2. male and non-pregnant female patient aged 18 to 70. 3. patients who understand the conditions of the study and are willing to participate for the length of the prescribed follow-up. exclusion criteria: 1. patients requiring total hip replacement surgery for a fresh hip fracture. 2. patients with inflammatory arthritis 3. patients with metabolic bone disease or taking drugs that affect bone turnover. 4 .patients requiring revision surgery of a previously implanted total hip replacement system or patients requiring a conversion surgery from a previous fracture fixation or hip fusion. 5. patients with presence of malignancy in the area of the involved hip joint. 6. patients who, as judged by the surgeon, are mentally incompetent or are reasonably unlikely to be compliant with the prescribed postoperative routine and the follow-up evaluation schedule. 7. patients with other concurrent illnesses that are likely to affect their outcome such as sickle cell anaemia, systemic lupus erythematosus or renal disease requiring dialysis.
the relationship between functional constipation and sacroiliac joint dysfunction

Conditions: Constipation - Functional; Sacroiliac Joint Somatic Dysfunction

Summary: the purpose of this study; to compare individuals with and without chronic constipation in terms of sacroiliac joint dysfunction and to examine the relationship between chronic constipation and sacroiliac joint.

constipation is a heterogeneous, polysymptomatic and multifactorial disease. many symptoms are used to define the term constipation, such as hard stool, excessive straining, few bowel movements, use of digital maneuvers during defecation, abdominal bloating, and a feeling of inadequate evacuation. chronic constipation is seen in approximately 14% of the world. it is seen on average 2 times more in women. visceral and somatic neural control of defecation is provided by the sacral 2-4 segments of the spinal cord. it is in neural relationship with the sacroiliac joint and pelvic floor muscles, which also provide innervation from the same segments. these visceral and somatic structures can affect each other through viscerosomatic and somatovisceral reflexes. this means that an afferent input from the rectum can reflect on and around the sacroiliac joint. based on this connection, we think that primary chronic constipation without an organic cause may be associated with sacroiliac joint dysfunction. in the literature review, no study examining this relationship was found. this study is planned to evaluate individuals with and without chronic constipation in terms of sacroiliac joint dysfunction and to examine the relationship between chronic constipation and sacroiliac joint.

Eligibility criteria:
inclusion criteria (for functional constipation group): * voluntary participation in the research * fulfill the diagnostic criteria for functional constipation (rome iv) * being women * not using laxatives for at least the last 4 weeks inclusion criteria (for control group): * voluntary participation in the research * being women * not having functional constipation exclusion criteria: * having cooperation problems * being pregnant * being breast-feeding * taking medication for depression, hypertension, sleep disorders, and pain * having parkinson, stroke, spinal cord injury, multiple sclerosis, hypothyroidism, diabetes mellitus, cerebral palsy, thyroid problems, cancer, presence of tumor, presence of hernia, endometriosis, neuropathy, myopathy, scleroderma, inflammatory bowel diseases (crohn, gastrointestinal tuberculosis, celiac, colon diverticulum, colonoscopy), cognitive impairment * having neurological or metabolic or malignant disorders * having a history of open abdominal surgery * having a history of pelvic and abdominal radiotherapy

Keywords: constipation women rehabilitation
parenting and cah - 21-hydroxylase deficiency

Conditions: CAH - 21-Hydroxylase Deficiency

Summary: congenital adrenal hyperplasia (cah) is a genetic disease with autosomal recessive transmission, which is defined by a deficiency of one of the steroidogenesis enzymes. 21-hydroxylase deficiency (21ohd), related to mutations of the cyp21a2 gene, is involved in 90 to 95% of cah cases. depending on the severity of the mutations of this gene, there are severe forms known as "classic" (fc), with neonatal onset, and moderate forms known as "non-classic" (fnc), with onset later in childhood or after puberty. the classic form includes the salt-wasting form and the pure virilizing form, depending on the degree of aldosterone deficiency. the sexuality and fertility of women with classic 21ohd deficiency are impaired by several factors such as disruption of the gonadotropic axis due to overproduction of androgens and progesterone by the adrenal glands, and mechanical and psychological factors related to genital surgery. the fertility of these women improves over time, largely due to earlier treatment of cah, improved therapeutic compliance and surgical advances in genital reconstruction leading to an increase in the percentage of patients who are sexually active. however, there is little data available, and even less on the course of pregnancy, its complications and its outcomes.


Eligibility criteria:
inclusion criteria: * patients aged 18 or over * patients with hcs due to 21-hydroxylase deficiency, confirmed genetically * patients who have been informed and do not object to participating in the research exclusion criteria: * patients who do not speak french * patients who are not affiliated to a social security scheme or who are not entitled to it * patients under legal protection, or under guardianship or trusteeship.

Keywords: congenital adrenal hyperplasia due to 21 hydroxylase deficiency fertility pregnancy outcomes pregnancy related hormonal substitution parental project
the efficacy and safety of huai er in the adjuvant treatment of covid-19

Conditions: COVID-19

Summary: in december 2019,a new type of pneumonia caused by the coronavirus (covid-2019) broke out in wuhan ,china, and spreads quickly to other chinese cities and 28 countries. more than 70000 people were infected and over 2000 people died all over the world.there is no specific drug treatment for this disease. this study is planned to observe the efficacy and safety of huaier granule in the adjuvant treatment covid-19.


Eligibility criteria:
inclusion criteria: 1. aged between 18 and 75 years, extremes included, male or female 2. patients diagnosed with mild or common type covid-19, according to the official guideline "pneumonia diagnosis and treatment scheme for novel coronavirus infection (trial version 6)" 3. patients can generally tolerable for treatment recommended by the official guideline "pneumonia diagnosis and treatment scheme for novel coronavirus infection (trial version 6)" 4. patients have not been accompanied by serious physical diseases of heart, lung, brain, etc.,eastern cooperative oncology group score standard:0-1 5. ability to understand and the willingness to sign a written informed consent document. exclusion criteria: 1. female subjects who are pregnant or breastfeeding. 2. patients who are allergic to this medicine 3. patients meet the contraindications of huaier granule 4. patients with diabetes 5. patients have any condition that in the judgement of the investigators would make the subject inappropriate for entry into this study. 6. patients can't take drugs orally

Keywords: covid-19 huaier granule